This study focuses on patients with platinum-resistant advanced high-grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. The research evaluates a medication called mirvetuximab soravtansine, which is given as a solution through intravenous infusion. The study aims to test different dosing schedules of this medication to determine which one works best while causing the least side effects.
The study involves two main groups of patients. The first group will receive the medication according to different dosing schedules, while patients with moderate liver problems will be studied separately to find the right starting dose for them. During treatment, patients will receive the medication every three weeks as part of a 21-day cycle. The study will also use prednisolone acetate eye drops and lubricating eye drops as supportive care.
The research team will monitor patients for treatment effectiveness and any side effects, particularly paying attention to eye-related effects. They will track how the cancer responds to treatment through regular medical examinations and imaging tests. The study will also measure how long the treatment keeps working and how long patients survive after starting the treatment.
Belgium 
France 
Poland 
Spain 
